Completed PHASE3 INTERVENTIONAL 2-arm NCT00626288

Mesalazine Therapy in Patients With Irritable Bowel Syndrome (IBS-02/07)

A Randomised Controlled Multicenter Trial Assessing the Efficacy and Safety of Mesalazine Therapy in Patients With Irritable Bowel Syndrome.

Sponsor: SOFAR S.p.A.

Conditions Irritable Bowel Syndrome

Interventions Mesalazine Placebo

Updated 6 times since 2017 Last updated: Jul 25, 2013 Started: Dec 31, 2007 Primary completion: Mar 31, 2012 Completion: Jul 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00626288, this PHASE3 trial focuses on Irritable Bowel Syndrome and remains completed. Sponsored by SOFAR S.p.A., it has been updated 6 times since 2007, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Dec 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

SOFAR S.p.A.

Data source: SOFAR S.p.A.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ancona, Italy , Belluno, Italy , Bologna, Italy , Cento, Italy , Chieti, Italy , Florence, Italy , Foggia, Italy , Lagosanto, Italy , Mestre, Italy , Milan, Italy and 7 more locations